merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks outweighing modest benefits; lack of correlation between plaque removal and clinical response</answer>
<question_number>2</question_number>
<answer>Discourages participation in trials for potentially better treatments, slowing development of other Alzheimer's therapies</answer>
<question_number>3</question_number>
<answer>No correlation between amyloid plaque removal and clinical response in individual patients</answer>
<question_number>4</question_number>
<answer>Raises concerns and negatively impacts perception of Kisunla's safety due to higher rates of serious side effects</answer>
<question_number>5</question_number>
<answer>Potential discontinuation after amyloid clearance reduces overall cost, justifying higher annual price</answer>
<question_number>6</question_number>
<answer>May decrease patients' willingness to join other clinical trials, hindering development of better treatments</answer>
<question_number>7</question_number>
<answer>Allows discontinuation after amyloid clearance and requires less frequent dosing, reducing treatment inconvenience</answer>
<question_number>8</question_number>
<answer>Amyloid protein</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Patients with intermediate tau levels declined more slowly, suggesting earlier treatment is more effective</answer>